A Pharmaceutical Industry Perspective on Transporter and CYP-Mediated Drug–Drug Interactions: Kidney Transporter Biomarkers

References

• Morrissey KM , StockerSL, WittwerMB, XuL, GiacominiKM. Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol.53, 503–529 (2013).
   PubMed Web of Science ®Google Scholar
• Ivanyuk A , LivioF, BiollazJ, BuclinT. Renal drug transporters and drug interactions. Clin. Pharmacokinet.56 (8), 825–892 (2017).
   PubMed Web of Science ®Google Scholar
• Feng B , VarmaMV. Evaluation and quantitative prediction of renal transporter-mediated drug–drug interactions. J. Clin. Pharmacol.56 (Suppl. 7), S110–S121 (2016).
   PubMedGoogle Scholar
• Elsby R , ChidlawS, OutteridgeSet al. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. Pharmacol. Res. Perspect.5 (5), doi:10.1002/prp2.357 (2017).
   PubMed Web of Science ®Google Scholar
• Song IH , ZongJ, BorlandJet al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J. Acquir. Immune Defic. Syndr.72 (4), 400–407 (2016).
   PubMed Web of Science ®Google Scholar
• Tsuda M , TeradaT, UebaMet al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther.329 (1), 185–191 (2009).
   PubMed Web of Science ®Google Scholar
• Ito S , KusuharaH, YokochiMet al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug–drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther.340 (2), 393–403 (2012).
   PubMed Web of Science ®Google Scholar
• Shen H , YangZ, ZhaoW, ZhangY, RodriguesAD. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metabol. Dispos. Biol. Fate Chem.41 (12), 2095–2103 (2013).
   PubMed Web of Science ®Google Scholar
• Lee SC , AryaV, YangX, VolpeDA, ZhangL. Evaluation of transporters in drug development: current status and contemporary issues. Adv. Drug Deliv. Rev.116, 100–118 (2017).
   PubMed Web of Science ®Google Scholar
• Tweedie D , PolliJW, BerglundEGet al. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin. Pharmacol. Ther.94 (1), 113–125 (2013).
   PubMed Web of Science ®Google Scholar
• Yin J , DuanH, WangJ. Impact of substrate-dependent inhibition on renal organic cation transporters hOCT2 and hMATE1/2-K-mediated drug transport and intracellular accumulation. J. Pharmacol. Exp. Ther.359 (3), 401–410 (2016).
   PubMed Web of Science ®Google Scholar
• Hacker K , MaasR, KornhuberJ, FrommMF, ZolkO. Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates. PLoS ONE10 (9), e0136451 (2015).
   PubMed Web of Science ®Google Scholar
• Belzer M , MoralesM, JagadishB, MashEA, WrightSH. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J. Pharmacol. Exp. Ther.346 (2), 300–310 (2013).
   PubMed Web of Science ®Google Scholar
• Shitara Y , SatoH, SugiyamaY. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.45, 689–723 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner C , ZhaoP, PanYet al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA Public Workshop on PBPK. CPT Pharmacometrics Syst. Pharmacol.4 (4), 226–230 (2015).
   PubMedGoogle Scholar
• Pan Y , HsuV, GrimsteinMet al. The application of physiologically based pharmacokinetic modeling to predict the role of drug transporters: scientific and regulatory perspectives. J. Clin. Pharmacol.56 (Suppl. 7), S122–S131 (2016).
   PubMedGoogle Scholar
• Chu X , ChanGH, EversR. Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions. J. Pharm. Sci.106 (9), 2357–2367 (2017).
   PubMed Web of Science ®Google Scholar
• Rodrigues AD , TaskarKS, KusuharaH, SugiyamaY. Endogenous probes for drug transporters: balancing vision with reality. Clin. Pharmacol. Ther.103 (3), 434–448 (2017).
   PubMed Web of Science ®Google Scholar
• Mariappan TT , ShenH, MaratheP. Endogenous biomarkers to assess drug–drug interactions by drug transporters and enzymes. Curr. Drug Metab.18 (8), 757–768 (2017).
   PubMed Web of Science ®Google Scholar
• Imamura Y , TsuruyaY, DammeKet al. 6beta-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Drug Metabol. Dispos. Biol. Fate Chem.42 (4), 685–694 (2014).
   PubMed Web of Science ®Google Scholar
• Tsuruya Y , KatoK, SanoYet al. Investigation of endogenous compounds applicable to drug-drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metabol. Dispos. Biol. Fate Chem.44 (12), 1925–1933 (2016).
   PubMed Web of Science ®Google Scholar
• Shen H , NelsonDM, OliveiraRVet al. Discovery and validation of pyridoxic acid and homovanillic acid as novel endogenous plasma biomarkers of organic anion transporter (OAT) 1 and OAT3 in cynomolgus monkeys. Drug Metabol. Dispos. Biol. Fate Chem.46 (2), 178–188 (2017).
   PubMed Web of Science ®Google Scholar
• Chu X , BleasbyK, ChanGH, NunesI, EversR. Transporters affecting biochemical test results: creatinine-drug interactions. Clin. Pharmacol. Ther.100 (5), 437–440 (2016).
   PubMed Web of Science ®Google Scholar
• Chu X , BleasbyK, ChanGH, NunesI, EversR. The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist?Drug Metabol. Dispos. Biol. Fate Chem.44 (9), 1498–1509 (2016).
   PubMedGoogle Scholar
• Shen H , LaiY, RodriguesAD. Organic anion transporter 2: an enigmatic human solute carrier. Drug Metabol. Dispos. Biol. Fate Chem.45 (2), 228–236 (2017).
   PubMed Web of Science ®Google Scholar
• Chu X , BleasbyK, ChanGH, NunesI, EversR. The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist?Drug Metabol. Dispos. Biol. Fate Chem.44 (9), 1498–1509 (2016).
   PubMedGoogle Scholar
• Ito S , KusuharaH, KumagaiYet al. N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther.92 (5), 635–641 (2012).
   PubMed Web of Science ®Google Scholar
• Muller F , PontonesCA, RennerBet al. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. Eur. J. Clin. Pharmacol.71 (1), 85–94 (2015).
   PubMed Web of Science ®Google Scholar
• Bergagnini-Kolev MC , HebertMF, EasterlingTR, LinYS. Pregnancy increases the renal secretion of N1-methylnicotinamide, an endogenous probe for renal cation transporters, in patients prescribed metformin. Drug Metabol. Dispos. Biol. Fate Chem.45 (3), 325–329 (2017).
   PubMed Web of Science ®Google Scholar
• Kitamura S , NittaK, TayamaYet al. Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metabol. Dispos. Biol. Fate Chem.36 (7), 1202–1205 (2008).
   PubMed Web of Science ®Google Scholar
• Shen H , DaiJ, LiuTet al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J. Pharmacol. Exp. Ther.357 (2), 382–393 (2016).
   PubMed Web of Science ®Google Scholar
• Wikoff WR , NagleMA, KouznetsovaVL, TsigelnyIF, NigamSK. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J. Proteome Res.10 (6), 2842–2851 (2011).
   PubMed Web of Science ®Google Scholar
• Yee SW , GiacominiMM, HsuehCHet al. Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1. Clin. Pharmacol. Ther.100 (5), 524–536 (2016).
   PubMed Web of Science ®Google Scholar
• Dong Z , YangX, AryaV, ZhangL. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity (NME) to inhibit organic anion transporter 1 and 3 (OAT1 and 3). Clin. Pharmacol. Ther.99 (S1), S99 (2017).
   Google Scholar